全文获取类型
收费全文 | 92920篇 |
免费 | 5258篇 |
国内免费 | 3058篇 |
专业分类
耳鼻咽喉 | 525篇 |
儿科学 | 2867篇 |
妇产科学 | 2198篇 |
基础医学 | 7225篇 |
口腔科学 | 2209篇 |
临床医学 | 9250篇 |
内科学 | 18168篇 |
皮肤病学 | 977篇 |
神经病学 | 3904篇 |
特种医学 | 3674篇 |
外科学 | 7701篇 |
综合类 | 14666篇 |
现状与发展 | 1篇 |
一般理论 | 14篇 |
预防医学 | 9568篇 |
眼科学 | 2532篇 |
药学 | 5903篇 |
5篇 | |
中国医学 | 5103篇 |
肿瘤学 | 4746篇 |
出版年
2024年 | 88篇 |
2023年 | 651篇 |
2022年 | 570篇 |
2021年 | 834篇 |
2020年 | 790篇 |
2019年 | 382篇 |
2018年 | 1100篇 |
2017年 | 1051篇 |
2016年 | 1226篇 |
2015年 | 1218篇 |
2014年 | 1349篇 |
2013年 | 1858篇 |
2012年 | 3568篇 |
2011年 | 6572篇 |
2010年 | 3523篇 |
2009年 | 2657篇 |
2008年 | 4632篇 |
2007年 | 4266篇 |
2006年 | 4025篇 |
2005年 | 5157篇 |
2004年 | 9585篇 |
2003年 | 8959篇 |
2002年 | 7041篇 |
2001年 | 5610篇 |
2000年 | 2854篇 |
1999年 | 3372篇 |
1998年 | 2521篇 |
1997年 | 2149篇 |
1996年 | 1384篇 |
1995年 | 1188篇 |
1994年 | 1213篇 |
1993年 | 1791篇 |
1992年 | 1529篇 |
1991年 | 1305篇 |
1990年 | 999篇 |
1989年 | 860篇 |
1988年 | 652篇 |
1987年 | 544篇 |
1986年 | 531篇 |
1985年 | 265篇 |
1984年 | 152篇 |
1983年 | 91篇 |
1982年 | 87篇 |
1981年 | 83篇 |
1980年 | 60篇 |
1979年 | 78篇 |
1978年 | 63篇 |
1977年 | 62篇 |
1975年 | 67篇 |
1974年 | 59篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
22.
分子靶向药物bevacizumab是针对血管内皮生长因子(VEGF)的重组人源化单克隆抗体,在多种恶性肿瘤的治疗中显示了临床效果。现就bevacizumab的作用机制及其在乳腺癌治疗中的临床研究进展作一综述。 相似文献
23.
24.
百年乐与人参黄芪合剂对心血管系统的药理作用比较 总被引:1,自引:1,他引:0
百年乐和人参黄芪合剂对心血管系统的作用研究表明:百年乐能加速小鼠肠系膜微循环障碍的恢复,增加离体兔耳血管的流量,使主动脉平滑肌松弛,对抗心肌缺氧,抑制血栓形成,其作用强于人参黄芪合剂。 相似文献
25.
从土藿香根中得到两个二萜化合物,藿香酚(2)及异藿香酚(3)。经光谱解析(IR,UV,HRMS及NMR谱),确定它们的结构分别为11,14dihydroxy12methoxy19(4→3)abeoabieta4,(18),8,11,13tetraen7one(2)和11,14dihydroxy12methoxy19(4→3)abeoabieta3,8,11,13tetraen7one(3)藿香酚(2)为一新的化合物,而异藿香酚(3)系首次从天然界分离得到,二者为一对异构体。 相似文献
26.
王伏虎 《南京医科大学学报(英文版)》2002,16(2):49-64
Stroke is a debilitating disease that affects millions each year.While in many cases cerebral ischemic in jury can be limited by effectivw resuscitation or thrombolytic treatment,the injured neurons wither in a process known as delayed neuronal death(DND).Mounting evidence indicates that DND is not simply necrosis played out in slow motion but apoptosis is triggered.Of particular interest are two groups of signal proteins that participate in apoptosis-cyclin dependent kinases(CDKs) and p53-among a myriad of signaling events after an ischemic insult.Recent investigations have shown that CDKs,a family of enzymes initially known for their role in cell cycle regulation,are activated in injured neurons in DND.As for p53,new reports suggest that its up-regulation may represent a failed attempt to rescue in jured neurons,although its up-regulation was previously considered an indication of apoptosis.These observations thus rekindle an old quest to identify new neuroprotective targets to minimize the stroke damage.In this review,the author will examine the evidence that indicates the participation of CDKs and p53 in DND and then introduce pre-clinical data to explore CDK inhibition as a potential neuroprotective target.Finally,using CDK inhibition as an example,this paper will discuss the pertinent criteria for a viable neuroprotective strategy for ischemic in jury. 相似文献
27.
本文选择34颗有银汞充填体悬突的患牙,采用金刚砂钻和银汞磨光钻去除悬突,并观察去除悬突前后部分牙周组织的变化、结果表明银汞充填体悬突危害牙周组织的健康.去除悬突并协同口腔卫生宣教、可促进牙周组织的恢复. 相似文献
28.
放射性肝纤维化过程的定量研究 总被引:6,自引:0,他引:6
经^60Coγ线照射大鼠肝区,通过光镜、电镜和图像分析仪、宣研究了照后1年肝脏的病理改变。结果表明,30Gy组在照射后1年内逐渐发生了放射性肝纤维化病变。在肝纤维化发生过程中,肝细胞内糖原颗凿含量进行性减少,间质中胶原纤维含量进行性增加,网状纤维于照射1-3个月呈进行性增加。 相似文献
29.
为提供微波辐射安全标准必要的数据,研究了不同极化方向微波辐射能量对猕猴的影响。实验在医学微波无反射室中进行,分为电场,磁场和微波传输方向极化组,辐射频率1GHz,用红外热图技术,对暴露在三种极化方向电磁场中猕猴面部各解剖特片部位及胸部在辐射前后进行温度变化的定量分析。 相似文献
30.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献